Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2009

Achaogen Scores $26.6M Five-Year Contract Covering Biothreat Bacterial Strains

  • Achaogen received a $26.6 million contract spanning five years from the NIAID. The money will fund the discovery and development of compounds to combat biothreat strains of Gram-negative bacteria such as Yersinia pestis and Francisella tularensis.

    The NIAID funding will support work to extend the spectrum and efficacy of its current leads and to advance one neoglycoside through Phase I trials.

    Achaogen reports that its neoglycosides, or next-generation aminoglycosides, have shown broad-spectrum efficacy in vitro and in vivo against a wide range of multidrug resistant Gram-negative organisms as well as multidrug resistant Gram-positive bacteria. These include Pseudomonas, Acinetobacter, Enterobacteriaceae, MRSA, and vancomycin-resistant Staphylococcus strains.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »